{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T19:34:00Z","timestamp":1794339240605,"version":"4.9.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-023-03381-z","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T06:03:05Z","timestamp":1683093785000},"page":"368-378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7055-2407","authenticated-orcid":false,"given":"Sofia","family":"Gronskaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6674-6441","authenticated-orcid":false,"given":"Zhanna","family":"Belaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7041-0732","authenticated-orcid":false,"given":"Liudmila","family":"Rozhinskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9783-3599","authenticated-orcid":false,"given":"Elizaveta","family":"Mamedova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9124-294X","authenticated-orcid":false,"given":"Maria","family":"Vorontsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4564-2168","authenticated-orcid":false,"given":"Alexander","family":"Solodovnikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2320-1051","authenticated-orcid":false,"given":"Olga","family":"Golounina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5634-7877","authenticated-orcid":false,"given":"Galina","family":"Melnichenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"3381_CR1","doi-asserted-by":"publisher","unstructured":"J.P. Bilezikian, A.A. Khan, S.J. Silverberg, G.E.-H. Fuleihan, C. Marcocci, S. Minisola, N. Perrier, A. Sitges-Serra, R.V. Thakker, G. Guyatt, M. Mannstadt, J.T. Potts, B.L. Clarke, M.L. Brandi. On behalf of the International Workshop on Primary Hyperparathyroidism Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop 2022. https:\/\/doi.org\/10.1002\/jbmr.4677","DOI":"10.1002\/jbmr.4677"},{"issue":"3","key":"3381_CR2","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-19-0316","volume":"181","author":"J Bollerslev","year":"2019","unstructured":"J. Bollerslev, C. Schalin-J\u00e4ntti, L. Rejnmark, H. Siggelkow, H. Morreau, R. Thakker, A. Sitges-Serra, F. Cetani, C. Marcocci, Management of endocrine disease: Unmet therapeutic, educational and scientific needs in parathyroid disorders. Eur. J. Endocrinol. 181(3), P1\u2013P19 (2019). https:\/\/doi.org\/10.1530\/EJE-19-0316","journal-title":"Eur. J. Endocrinol."},{"key":"3381_CR3","doi-asserted-by":"publisher","unstructured":"S. Minisola, A. Arnold, Z. Belaya, M.L. Brandi, B.L. Clarke, F.M. Hannan, L.C. Hofbauer, K.L. Insogna, A. Lacroix, U. Liberman, A. Palermo, J. Pepe, R. Rizzoli, R. Wermers, R.V. Thakker, Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism. J. Bone Min. Res. 2022 Aug. https:\/\/doi.org\/10.1002\/jbmr.4665","DOI":"10.1002\/jbmr.4665"},{"issue":"Suppl 2","key":"3381_CR4","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1002\/jbmr.5650061409","volume":"6","author":"LJ Melton 3rd","year":"1991","unstructured":"L.J. Melton 3rd, Epidemiology of primary hyperparathyroidism. J. Bone Min. Res. 6(Suppl 2), S25\u2013S30 (1991). https:\/\/doi.org\/10.1002\/jbmr.5650061409","journal-title":"J. Bone Min. Res."},{"issue":"2","key":"3381_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrendo.2017.104","volume":"14","author":"MD Walker","year":"2018","unstructured":"M.D. Walker, S.J. Silverberg, Primary hyperparathyroidism. Nat. Rev. Endocrinol. 14(2), 115\u2013125 (2018). https:\/\/doi.org\/10.1038\/nrendo.2017.104","journal-title":"Nat. Rev. Endocrinol."},{"issue":"Nov 8","key":"3381_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1530\/EC-17-0126","volume":"6","author":"E Mamedova","year":"2017","unstructured":"E. Mamedova, N. Mokrysheva, E. Vasilyev, V. Petrov, E. Pigarova, S. Kuznetsov, N. Kuznetsov, L. Rozhinskaya, G. Melnichenko, I. Dedov, A. Tiulpakov, Primary hyperparathyroidism in young patients in Russia: high frequency of hyperparathyroidism-jaw tumor syndrome. Endocr. Connect 6(Nov 8), 557\u2013565 (2017). https:\/\/doi.org\/10.1530\/EC-17-0126","journal-title":"Endocr. Connect"},{"issue":"9","key":"3381_CR7","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1001\/jamasurg.2017.1721","volume":"152","author":"AE Stephen","year":"2017","unstructured":"A.E. Stephen, M. Mannstadt, R.A. Hodin, Indications for surgical management of hyperparathyroidism: a review. JAMA Surg. 152(9), 878\u2013882 (2017). https:\/\/doi.org\/10.1001\/jamasurg.2017.1721","journal-title":"JAMA Surg."},{"key":"3381_CR8","doi-asserted-by":"publisher","unstructured":"J. Bollerslev, L. Rejnmark, A. Zahn, A. Heck, N.M. Appelman-Dijkstra, L. Cardoso, F.M. Hannan, F. Cetani, T. Sikj\u00e6r, A.M. Formenti, S. Bj\u00f6rnsdottir, C. Schalin-Jantti, Z. Belaya, F.W. Gibb, B. Lapauw, K. Amrein, C. Wicke, C. Grasemann, M. Krebs, E.M. Ryh\u00e4nen, O. Makay, S. Minisola, S. Gaujoux, J.P. Bertocchio, Z.K. Hassan-Smith, A. Linglart, E.M. Winter, M. Kollmann, H.G. Zmierczak, E. Tsourdi, S. Pilz, H. Siggelkow, N.J. Gittoes, C. Marcocci, P. Kamenicky, European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders. Eur. J. Endocrinol. 2021 Dec:EJE-21-1044.R1. https:\/\/doi.org\/10.1530\/EJE-21-1044","DOI":"10.1530\/EJE-21-1044"},{"key":"3381_CR9","doi-asserted-by":"publisher","unstructured":"J.S. Leere, J. Karmisholt, M. Robaczyk, P. Vestergaard, Contemporary medical management of primary hyperparathyroidism: a systematic review. Front. Endocrinol. 8, (2017). https:\/\/doi.org\/10.3389\/fendo.2017.00079","DOI":"10.3389\/fendo.2017.00079"},{"issue":"10","key":"3381_CR10","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1359\/JBMR.040708","volume":"19","author":"L Wang","year":"2004","unstructured":"L. Wang, L. Quarles, R. Spurney, Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH (1\u201334). J. Bone Min. Res. 19(10), 1661\u20131670 (2004). https:\/\/doi.org\/10.1359\/JBMR.040708","journal-title":"J. Bone Min. Res."},{"issue":"9","key":"3381_CR11","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1210\/endo.142.9.8356","volume":"142","author":"Y Ma","year":"2001","unstructured":"Y. Ma, R. Cain, D. Halladay, X. Yang, Q. Zeng, R. Miles, S. Chandrasekhar, T. Martin, J. Onyia, Catabolic effects of continuous human PTH (1\u201338) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and geneassociated bone formation. Endocrinology 142(9), 4047\u20134054 (2001). https:\/\/doi.org\/10.1210\/endo.142.9.8356","journal-title":"Endocrinology"},{"issue":"Oct 2","key":"3381_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/jcb.10623","volume":"90","author":"Y Ueno","year":"2003","unstructured":"Y. Ueno, T. Shinki, Y. Nagai, H. Murayama, K. Fujii, T. Suda, In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J. Cell Biochem 90(Oct 2), 267\u2013277 (2003). https:\/\/doi.org\/10.1002\/jcb.10623","journal-title":"J. Cell Biochem"},{"issue":"3","key":"3381_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1530\/EJE-07-0528","volume":"158","author":"AD Anastasilakis","year":"2008","unstructured":"A.D. Anastasilakis, D.G. Goulis, S.A. Polyzos, S. Gerou, V. Pavlidou, G. Koukoulis, A. Avramidis, Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kB ligand levels in women with established osteoporosis treated with teriparatide. Eur. J. Endocrinol. 158(3), 411\u2013415 (2008). https:\/\/doi.org\/10.1530\/EJE-07-0528","journal-title":"Eur. J. Endocrinol."},{"issue":"Jul 1","key":"3381_CR14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.bone.2004.03.012","volume":"35","author":"L Stilgren","year":"2004","unstructured":"L. Stilgren, E. Rettmer, E. Eriksen, L. Hegedus, H. Beck-Nielsen, B. Abrahamsen, Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kb ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with. Bone Metab. Bone 35(Jul 1), 256\u2013265 (2004). https:\/\/doi.org\/10.1016\/j.bone.2004.03.012","journal-title":"Bone Metab. Bone"},{"issue":"11","key":"3381_CR15","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","volume":"5","author":"S Khosla","year":"2017","unstructured":"S. Khosla, L.C. Hofbauer, Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 5(11), 898\u2013907 (2017). https:\/\/doi.org\/10.1016\/S2213-8587(17)30188-2","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"Aug 8","key":"3381_CR16","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"S.R. Cummings, J. San Martin, M.R. McClung, E.S. Siris, R. Eastell, I.R. Reid, P. Delmas, H.B. Zoog, M. Austin, A. Wang, S. Kutilek, S. Adami, J. Zanchetta, C. Libanati, S. Siddhanti, C. Christiansen, Freedom Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361(Aug 8), 756\u2013765 (2009). https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"3381_CR17","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","volume":"26","author":"S Papapoulos","year":"2015","unstructured":"S. Papapoulos, K. Lippuner, C. Roux, C.J. Lin, D.L. Kendler, E.M. Lewiecki, M.L. Brandi, E. Czerwi\u0144ski, E. Franek, P. Lakatos, C. Mautalen, S. Minisola, J.Y. Reginster, S. Jensen, N.S. Daizadeh, A. Wang, M. Gavin, C. Libanati, R.B. Wagman, H.G. Bone, The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos. Int. 26(12), 2773\u20132783 (2015). https:\/\/doi.org\/10.1007\/s00198-015-3234-7","journal-title":"Osteoporos. Int."},{"issue":"10","key":"3381_CR18","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/jbmr.149","volume":"25","author":"IR Reid","year":"2010","unstructured":"I.R. Reid, P.D. Miller, J.P. Brown, D.L. Kendler, A. Fahrleitner-Pammer, I. Valter, K. Maasalu, M.A. Bolognese, G. Woodson, H. Bone, B. Ding, R.B. Wagman, J. San Martin, M.S. Ominsky, D.W. Dempster, Denosumab phase 3 bone Histology Study Group. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J. Bone Min. Res. 25(10), 2256\u20132265 (2010). https:\/\/doi.org\/10.1002\/jbmr.149","journal-title":"J. Bone Min. Res."},{"issue":"1","key":"3381_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.14341\/osteo9760","volume":"21","author":"ZE Belaya","year":"2018","unstructured":"Z.E. Belaya, J.P. Bilezikian, O.B. Ershova, O.M. Lesnyak, L.A. Marchenkova, S.S. Rodionova, L.Y. Rozhinskaya, N.V. Toroptsova, S.V. Yureneva, Long-term treatment options for postmenopausal osteoporosis: results of recent clinical studies of Denosumab. Osteoporos. Bone Dis. 21(1), 17\u201322 (2018). https:\/\/doi.org\/10.14341\/osteo9760","journal-title":"Osteoporos. Bone Dis."},{"key":"3381_CR20","doi-asserted-by":"publisher","unstructured":"E. Tsourdi, M.C. Zillikens, C. Meier, J.J. Body, E. Gonzalez Rodriguez, A.D. Anastasilakis, B. Abrahamsen, E. McCloskey, L.C. Hofbauer, N. Gua\u00f1abens, B. Obermayer-Pietsch, S.H. Ralston, R. Eastell, J. Pepe, A. Palermo, B. Langdahl, Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J. Clin. Endocrinol. Metab. 2020 Oct:dgaa756. https:\/\/doi.org\/10.1210\/clinem\/dgaa756","DOI":"10.1210\/clinem\/dgaa756"},{"issue":"9","key":"3381_CR21","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1007\/s00198-016-3607-6","volume":"27","author":"C Beaudoin","year":"2016","unstructured":"C. Beaudoin, S. Jean, L. Bessette, L.G. Ste-Marie, L. Moore, J.P. Brown, Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Osteoporos. Int. 2016 27(9), 2835\u20132844 (2016). https:\/\/doi.org\/10.1007\/s00198-016-3607-6","journal-title":"Osteoporos. Int. 2016"},{"issue":"8","key":"3381_CR22","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/jbmr.81","volume":"25","author":"E Seeman","year":"2010","unstructured":"E. Seeman, P.D. Delmas, D.A. Hanley, D. Sellmeyer, A.M. Cheung, E. Shane, A. Kearns, T. Thomas, S.K. Boyd, S. Boutroy, C. Bogado, S. Majumdar, M. Fan, C. Libanati, J. Zanchetta, Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J. Bone Min. Res. 25(8), 1886\u20131894 (2010). https:\/\/doi.org\/10.1002\/jbmr.81","journal-title":"J. Bone Min. Res."},{"issue":"7","key":"3381_CR23","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1007\/s00198-014-2692-7","volume":"25","author":"JP Brown","year":"2014","unstructured":"J.P. Brown, C. Roux, P.R. Ho, M.A. Bolognese, J. Hall, H.G. Bone, S. Bonnick, J.P. van den Bergh, I. Ferreira, P. Dakin, R.B. Wagman, C. Recknor, Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporos. Int. 25(7), 1953\u20131961 (2014). https:\/\/doi.org\/10.1007\/s00198-014-2692-7","journal-title":"Osteoporos. Int."},{"issue":"5","key":"3381_CR24","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1210\/jc.2018-02236","volume":"104","author":"H Lyu","year":"2019","unstructured":"H. Lyu, B. Jundi, C. Xu, S.K. Tedeschi, K. Yoshida, S. Zhao, S.U. Nigwekar, B.Z. Leder, D.H. Solomon, Comparison of denosumab vs. bisphosphonates in osteoporosis patients: a meta-analysis of randomized controlled trials. J. Clin. Endocrinol. Metab. 104(5), 1753\u20131765 (2019). https:\/\/doi.org\/10.1210\/jc.2018-02236","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"3381_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","volume":"8","author":"JS Leere","year":"2020","unstructured":"J.S. Leere, J. Karmisholt, M. Robaczyk, S. Lykkeboe, A. Handberg, E. Steinkohl, J. Br\u00f8ndum Fr\u00f8kj\u00e6r, P. Vestergaard, Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 8(5), 407\u2013417 (2020). https:\/\/doi.org\/10.1016\/S2213-8587(20)30063-2","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3381_CR26","doi-asserted-by":"publisher","unstructured":"H.G. Bone, R.B. Wagman, M.L. Brandi, J.P. Brown, R. Chapurlat, S.R. Cummings, E. Czerwi\u0144ski, A. Fahrleitner-Pammer, D.L. Kendler, K. Lippuner, J.Y. Reginster, C. Roux, J. Malouf, M.N. Bradley, N.S. Daizadeh, A. Wang, P. Dakin, N. Pannacciulli, D.W. Dempster, S. Papapoulos, 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the 2017 phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 5(7):513\u2013523. https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","DOI":"10.1016\/S2213-8587(17)30138-9"},{"issue":"Jan 2","key":"3381_CR27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1210\/clinem\/dgaa851","volume":"106","author":"A Broadwell","year":"2021","unstructured":"A. Broadwell, A. Chines, P.R. Ebeling, E. Franek, S. Huang, S. Smith, D. Kendler, O. Messina, P.D. Miller, Denosumab safety and efficacy among participants in the freedom extension study with mild to moderate chronic kidney disease. J. Clin. Endocrinol. Metab. 106(Jan 2), 397\u2013409 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgaa851","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"3381_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.14341\/probl201662460-84","volume":"62","author":"\u0415\u0410 Pigarova","year":"2016","unstructured":"\u0415\u0410 Pigarova, L.Y. Rozhinskaya, Z.E. Belaya, L.K. Dzeranova, T.L. Karonova, A.V. Ilyin, G.A. Melnichenko, I.I. Dedov, Russian association of endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Probl. Endocrinol. 62(4), 60\u201384 (2016). https:\/\/doi.org\/10.14341\/probl201662460-84","journal-title":"Probl. Endocrinol."},{"issue":"Jul 1","key":"3381_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"M. Ketteler, G.A. Block, P. Evenepoel, M. Fukagawa, C.A. Herzog, L. McCann, S.M. Moe, R. Shroff, M.A. Tonelli, N.D. Toussaint, M.G. Vervloet, M.B. Leonard, Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what\u2019s changed and why it matters. Kidney Int. 92(Jul 1), 26\u201336 (2017). https:\/\/doi.org\/10.1016\/j.kint.2017.04.006","journal-title":"Kidney Int."},{"issue":"Mar Suppl 2","key":"3381_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/nep.13014","volume":"22","author":"C Chiang","year":"2017","unstructured":"C. Chiang, The use of bone turnover markers in chronic kidney disease-mineral and bone disorders. Nephrol. (Carlton) 22(Mar Suppl 2), 11\u201313 (2017). https:\/\/doi.org\/10.1111\/nep.13014. PMID: 28429547","journal-title":"Nephrol. (Carlton)"},{"issue":"8","key":"3381_CR31","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"S.A. Jamal, O. Ljunggren, C. Stehman-Breen, S.R. Cummings, M.R. McClung, S. Goemaere, P.R. Ebeling, E. Franek, Y.C. Yang, O.I. Egbuna, S. Boonen, P.D. Miller, Effects of denosumab on fracture and bone mineral density by level of kidney function. J. Bone Min. Res. 26(8), 1829\u20131835 (2011). https:\/\/doi.org\/10.1002\/jbmr.403","journal-title":"J. Bone Min. Res."},{"issue":"3","key":"3381_CR32","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/jgs.15250","volume":"66","author":"C Eller-Vainicher","year":"2018","unstructured":"C. Eller-Vainicher, S. Palmieri, E. Cairoli, G. Goggi, A. Scillitani, M. Arosio, A. Falchetti, I. Chiodini, Protective effect of denosumab on bone in older women with primary hyperparathyroidism. J. Am. Geriatr. Soc. 66(3), 518\u2013524 (2018). https:\/\/doi.org\/10.1111\/jgs.15250","journal-title":"J. Am. Geriatr. Soc."},{"issue":"1","key":"3381_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.14341\/osteo12415","volume":"23","author":"LY Rozhinskaya","year":"2020","unstructured":"L.Y. Rozhinskaya, S.A. Gronskaya, E.O. Mamedova, Z.E. Belaya, G.A. Melnichenko, The comparative efficiency of denosumab treatment in patients with postmenopausal osteoporosis, primary hyperparathyroidism and glucocorticoid-induced osteoporosis in real clinical practice. Osteoporos. bone Dis. 23(1), 4\u201313 (2020). https:\/\/doi.org\/10.14341\/osteo12415","journal-title":"Osteoporos. bone Dis."},{"issue":"Aug","key":"3381_CR34","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13018-018-0865-3","volume":"13","author":"J Wu","year":"2018","unstructured":"J. Wu, Q. Zhang, G. Yan, X. Jin, Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis. J. Orthop. Surg. Res. 13(Aug), 194 (2018). https:\/\/doi.org\/10.1186\/s13018-018-0865-3","journal-title":"J. Orthop. Surg. Res."},{"issue":"May 9727","key":"3381_CR35","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/S0140-6736(10)60320-0","volume":"375","author":"RM Zebaze","year":"2010","unstructured":"R.M. Zebaze, A. Ghasem-Zadeh, A. Bohte, S. Iuliano-Burns, M. Mirams, R.I. Price, E.J. Mackie, E. Seeman, Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 375(May 9727), 1729\u20131736 (2010). https:\/\/doi.org\/10.1016\/S0140-6736(10)60320-0","journal-title":"Lancet"},{"issue":"Dec","key":"3381_CR36","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40268-016-0146-8","volume":"16","author":"H Matsuno","year":"2016","unstructured":"H. Matsuno, Assessment of distal radius bone mineral density in osteoporosis patients receiving denosumab, including those with rheumatoid arthritis and those receiving oral glucocorticoids. Drugs R. D. 16(Dec), 347\u2013353 (2016). https:\/\/doi.org\/10.1007\/s40268-016-0146-8","journal-title":"Drugs R. D."},{"issue":"5","key":"3381_CR37","doi-asserted-by":"publisher","first-page":"829","DOI":"10.4236\/ijcm.2014.514111","volume":"5","author":"D Segula","year":"2017","unstructured":"D. Segula, T. Nikolova, E. Marks, L. Ranganath, V. Mishra, Long term outcome of bisphosphonate therapy in patients with primary hyperparathyroidism. Int. J. Clin. Med. 5(5), 829\u2013835 (2017). https:\/\/doi.org\/10.4236\/ijcm.2014.514111","journal-title":"Int. J. Clin. Med."},{"issue":"10","key":"3381_CR38","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1530\/EC-20-0380","volume":"9","author":"A Eremkina","year":"2020","unstructured":"A. Eremkina, J. Krupinova, E. Dobreva, A. Gorbacheva, E. Bibik, M. Samsonova, A. Ajnetdinova, N. Mokrysheva, Denosumab for management of severe hypercalcemia in primary hyperparathyroidism. Endocr. Connect 9(10), 1019\u20131027 (2020). https:\/\/doi.org\/10.1530\/EC-20-0380","journal-title":"Endocr. Connect"},{"issue":"4","key":"3381_CR39","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1159\/000510625","volume":"93","author":"E Mamedova","year":"2020","unstructured":"E. Mamedova, A. Kolodkina, E.V. Vasilyev, V. Petrov, Z. Belaya, A. Tiulpakov, Successful use of denosumab for life-threatening hypercalcemia in a pediatric patient with primary hyperparathyroidism. Horm. Res Paediatr. 93(4), 272\u2013278 (2020). https:\/\/doi.org\/10.1159\/000510625","journal-title":"Horm. Res Paediatr."},{"issue":"7","key":"3381_CR40","doi-asserted-by":"publisher","first-page":"757","DOI":"10.29271\/jcpsp.2020.07.757","volume":"30","author":"M \u00c7alapkulu","year":"2020","unstructured":"M. \u00c7alapkulu, O.O. Gul, S. Cander, C. Ersoy, E. Erturk, M.F. Sagiroglu, O. Saraydaroglu, Control of refractory hypercalcemia with denosumab in a case of metastatic parathyroid carcinoma. J. Coll. Physicians Surg. Pak. 30(7), 757\u2013759 (2020). https:\/\/doi.org\/10.29271\/jcpsp.2020.07.757","journal-title":"J. Coll. Physicians Surg. Pak."},{"issue":"1","key":"3381_CR41","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/1319-2442.198239","volume":"28","author":"O Dahmani","year":"2017","unstructured":"O. Dahmani, C. Sophoclis, M. Kebir, D. Bouguern, A. Sakho, P. Demarchi, Denosumab for the treatment of bisphosphonate resistant hypercalcemia in a hemodialysis patient. Saudi J. Kidney Dis. Transpl. 28(1), 154\u2013157 (2017). https:\/\/doi.org\/10.4103\/1319-2442.198239","journal-title":"Saudi J. Kidney Dis. Transpl."},{"issue":"4","key":"3381_CR42","doi-asserted-by":"publisher","first-page":"e233665","DOI":"10.1136\/bcr-2019-233665","volume":"13","author":"Y Li","year":"2020","unstructured":"Y. Li, C.Y. Fan, A. Manni, W.F. Simonds, Pitfalls of using denosumab preoperatively to treat refractory severe hypercalcaemia. BMJ Case Rep. 13(4), e233665 (2020). https:\/\/doi.org\/10.1136\/bcr-2019-233665","journal-title":"BMJ Case Rep."},{"issue":"3","key":"3381_CR43","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s12020-020-02401-6","volume":"69","author":"D Miyaoka","year":"2020","unstructured":"D. Miyaoka, Y. Imanishi, E. Kato, N. Toi, Y. Nagata, M. Kurajoh, S. Yamada, M. Inaba, M. Emoto, Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism. Endocrine 69(3), 642\u2013649 (2020). https:\/\/doi.org\/10.1007\/s12020-020-02401-6","journal-title":"Endocrine"},{"issue":"24","key":"3381_CR44","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.2169\/internalmedicine.8618-16","volume":"56","author":"K Nitta","year":"2017","unstructured":"K. Nitta, A. Yajima, K. Tsuchiya, Management of osteoporosis in chronic kidney disease. Intern Med. 56(24), 3271\u20133276 (2017). https:\/\/doi.org\/10.2169\/internalmedicine.8618-16","journal-title":"Intern Med."},{"issue":"7","key":"3381_CR45","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"G.A. Block, H.G. Bone, L. Fang, E. Lee, D. Padhi, A single-dose study of denosumab in patients with various degrees of renal impairment. J. Bone Min. Res. 27(7), 1471\u20131479 (2012). https:\/\/doi.org\/10.1002\/jbmr.1613","journal-title":"J. Bone Min. Res."},{"issue":"11","key":"3381_CR46","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/pds.4045","volume":"25","author":"ALH Huynh","year":"2016","unstructured":"A.L.H. Huynh, S.T. Baker, A.J. Stewardson, D.F. Johnson, Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. Pharmacoepidemiol Drug Saf. 25(11), 1274\u20131278 (2016). https:\/\/doi.org\/10.1002\/pds.4045","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"2","key":"3381_CR47","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000380960","volume":"41","author":"V Dave","year":"2015","unstructured":"V. Dave, C.Y. Chiang, J. Booth, P.F. Mount, Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5. Am. J. Nephrol. 41(2), 129\u2013137 (2015). https:\/\/doi.org\/10.1159\/000380960","journal-title":"Am. J. Nephrol."},{"key":"3381_CR48","doi-asserted-by":"publisher","first-page":"7384763","DOI":"10.1155\/2018\/7384763","volume":"2018","author":"R Jalleh","year":"2018","unstructured":"R. Jalleh, G. Basu, R. Le Leu, S. Jesudason, Denosumab-induced severe hypocalcaemia in chronic kidney disease. Case Rep. Nephrol. 2018, 7384763 (2018). https:\/\/doi.org\/10.1155\/2018\/7384763","journal-title":"Case Rep. Nephrol."},{"issue":"2","key":"3381_CR49","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40620-016-0334-1","volume":"30","author":"F Festuccia","year":"2017","unstructured":"F. Festuccia, M.T. Jafari, A. Moioli, C. Fofi, S. Barberi, S. Amendola, S. Sciacchitano, G. Punzo, P. Men\u00e8, Safety and efficacy of denosumab in osteoporotic hemodialysed patients. J. Nephrol. 30(2), 271\u2013279 (2017). https:\/\/doi.org\/10.1007\/s40620-016-0334-1","journal-title":"J. Nephrol."},{"issue":"Jul","key":"3381_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.maturitas.2017.04.008","volume":"101","author":"P Anagnostis","year":"2017","unstructured":"P. Anagnostis, S.A. Paschou, G. Mintziori, I. Ceausu, H. Depypere, I. Lambrinoudaki, A. Mueck, F.R. P\u00e9rez-L\u00f3pez, M. Rees, L.M. Senturk, T. Simoncini, J.C. Stevenson, P. Stute, F.A. Tr\u00e9mollieres, D.G. Goulis, Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas 101(Jul), 23\u201330 (2017). https:\/\/doi.org\/10.1016\/j.maturitas.2017.04.008","journal-title":"Maturitas"},{"issue":"Mar 3","key":"3381_CR51","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00198-022-06667-6","volume":"34","author":"Z \u2018Belaya","year":"2023","unstructured":"Z. \u2018Belaya, L. Rozhinskaya, I. Dedov, O. Drapkina, V. Fadeev, O. Golounina, O. Lesnyak, E. Mamedova, G. Melnichenko, A. Petraikin, S. Rodionova, I. Skripnikova, O. Tkacheva, N. Toroptsova, S. Yureneva, J.A. Kanis, A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis. Osteoporos. Int 34(Mar 3), 429\u2013447 (2023). https:\/\/doi.org\/10.1007\/s00198-022-06667-6","journal-title":"Osteoporos. Int"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03381-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03381-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03381-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T08:14:28Z","timestamp":1687767268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03381-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["3381"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03381-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2273397\/v1","asserted-by":"object"}]},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"assertion":[{"value":"14 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors S.G., Z.B., E.M., M.V., A.S., O.G. and G.M. declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}